Organogenesis Holdings (ORGO)
Organogenesis Holdings on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
15.6M
Short interest
settlement 2026-10-15
21.2
Days to cover
-5.5 days vs prior
48.4%
Short share of volume
2026-11-02
453
Fails to deliver
settlement 2026-09-30
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ORGO is 15,590,713 shares, up 1,470,952 shares over the last month. Over the last 48 readings it ranged from 8,520,606 shares (29 November 2024) to 16,227,082 shares (15 May 2026). The latest reading sits at the top of that range. At the reported average volume of 737K shares a day that is 21.2 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/orgo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 15,590,713 | +3.9% | 736,923 | 21.16 |
| 2026-09-30 | 15,002,130 | +6.3% | 563,439 | 26.63 |
| 2026-09-15 | 14,119,761 | -0.9% | 750,274 | 18.82 |
| 2026-08-31 | 14,248,296 | +0.1% | 594,717 | 23.96 |
| 2026-08-14 | 14,234,946 | +6.9% | 1,212,530 | 11.74 |
| 2026-07-31 | 13,314,958 | +1.4% | 639,597 | 20.82 |
| 2026-07-15 | 13,129,255 | -4.9% | 779,045 | 16.85 |
| 2026-06-30 | 13,803,202 | +12.4% | 845,984 | 16.32 |
| 2026-06-15 | 12,276,392 | -7.7% | 784,438 | 15.65 |
| 2026-05-29 | 13,296,314 | -18.1% | 1,149,562 | 11.57 |
| 2026-05-15 | 16,227,082 | +2.3% | 1,915,586 | 8.47 |
| 2026-04-30 | 15,855,307 | +21.0% | 1,111,994 | 14.26 |
| 2026-04-15 | 13,098,705 | +2.4% | 3,464,732 | 3.78 |
| 2026-03-31 | 12,790,678 | +1.6% | 539,113 | 23.73 |
| 2026-03-13 | 12,589,968 | -0.2% | 875,798 | 14.38 |
| 2026-02-27 | 12,612,680 | -3.5% | 619,443 | 20.36 |
| 2026-02-13 | 13,072,172 | +0.3% | 541,474 | 24.14 |
| 2026-01-30 | 13,037,724 | +1.1% | 631,236 | 20.65 |
| 2026-01-15 | 12,892,111 | -0.9% | 967,888 | 13.32 |
| 2025-12-31 | 13,004,869 | +15.4% | 1,639,950 | 7.93 |
| 2025-12-15 | 11,267,548 | +4.1% | 1,484,291 | 7.59 |
| 2025-11-28 | 10,825,354 | -0.5% | 1,492,852 | 7.25 |
| 2025-11-14 | 10,880,975 | +2.2% | 4,747,128 | 2.29 |
| 2025-10-31 | 10,649,719 | -4.2% | 682,296 | 15.61 |
| 2025-10-15 | 11,110,375 | +3.2% | 565,150 | 19.66 |
| 2025-09-30 | 10,767,297 | -0.9% | 915,736 | 11.76 |
| 2025-09-15 | 10,862,542 | +6.6% | 1,016,083 | 10.69 |
| 2025-08-29 | 10,188,331 | +4.0% | 549,893 | 18.53 |
| 2025-08-15 | 9,797,166 | +0.1% | 814,500 | 12.03 |
| 2025-07-31 | 9,783,027 | +0.5% | 686,585 | 14.25 |
| 2025-07-15 | 9,731,517 | -4.7% | 1,010,302 | 9.63 |
| 2025-06-30 | 10,215,392 | -5.5% | 1,034,670 | 9.87 |
| 2025-06-13 | 10,806,635 | -6.0% | 1,050,601 | 10.29 |
| 2025-05-30 | 11,494,464 | -5.0% | 727,815 | 15.79 |
| 2025-05-15 | 12,101,482 | +2.8% | 2,542,092 | 4.76 |
| 2025-04-30 | 11,769,435 | +15.3% | 1,643,012 | 7.16 |
| 2025-04-15 | 10,205,835 | +2.1% | 1,399,993 | 7.29 |
| 2025-03-31 | 9,994,282 | +16.0% | 1,332,753 | 7.50 |
| 2025-03-14 | 8,615,328 | -0.1% | 1,764,562 | 4.88 |
| 2025-02-28 | 8,621,099 | -0.5% | 7,014,549 | 1.23 |
| 2025-02-14 | 8,666,323 | -1.0% | 270,590 | 32.03 |
| 2025-01-31 | 8,754,353 | -15.9% | 523,569 | 16.72 |
| 2025-01-15 | 10,415,740 | +0.2% | 570,255 | 18.27 |
| 2024-12-31 | 10,396,298 | -5.5% | 613,890 | 16.94 |
| 2024-12-13 | 10,998,854 | +29.1% | 1,225,864 | 8.97 |
| 2024-11-29 | 8,520,606 | -18.1% | 842,005 | 10.12 |
| 2024-11-15 | 10,408,686 | +6.3% | 737,367 | 14.12 |
| 2024-10-31 | 9,792,058 | -4.9% | 326,191 | 30.02 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ORGO volume is 48.4%, down 14.8 points over the last five sessions. Over the last 30 readings it ranged from 28.6% (28 October 2026) to 83.2% (1 October 2026). The latest reading is 13.5 points below the 30-session average of 61.9%, on 669K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 324K | 669K | 48.4% | 0 |
| 2026-10-30 | 243K | 385K | 63.1% | 18 |
| 2026-10-29 | 216K | 445K | 48.4% | 19,622 |
| 2026-10-28 | 260K | 909K | 28.6% | 6,824 |
| 2026-10-27 | 257K | 430K | 59.9% | 16 |
| 2026-10-26 | 198K | 314K | 63.2% | 0 |
| 2026-10-23 | 326K | 652K | 50.0% | 0 |
| 2026-10-22 | 259K | 360K | 71.8% | 0 |
| 2026-10-21 | 308K | 559K | 55.1% | 259 |
| 2026-10-20 | 238K | 414K | 57.4% | 432 |
| 2026-10-19 | 370K | 571K | 64.8% | 23,509 |
| 2026-10-16 | 544K | 771K | 70.6% | 42,288 |
| 2026-10-15 | 318K | 422K | 75.3% | 75 |
| 2026-10-14 | 244K | 355K | 68.7% | 873 |
| 2026-10-13 | 244K | 317K | 76.9% | 0 |
| 2026-10-12 | 188K | 242K | 77.7% | 0 |
| 2026-10-09 | 97K | 184K | 53.0% | 51 |
| 2026-10-08 | 108K | 227K | 47.6% | 1,600 |
| 2026-10-07 | 133K | 208K | 64.0% | 0 |
| 2026-10-06 | 165K | 276K | 59.9% | 48 |
| 2026-10-05 | 282K | 349K | 80.7% | 344 |
| 2026-10-02 | 130K | 175K | 74.2% | 0 |
| 2026-10-01 | 143K | 172K | 83.2% | 5,095 |
| 2026-09-30 | 123K | 225K | 54.7% | 82 |
| 2026-09-29 | 126K | 172K | 73.4% | 0 |
| 2026-09-28 | 62K | 113K | 55.0% | 0 |
| 2026-09-25 | 120K | 216K | 55.8% | 0 |
| 2026-09-24 | 89K | 185K | 47.9% | 0 |
| 2026-09-23 | 135K | 180K | 75.1% | 0 |
| 2026-09-22 | 81K | 158K | 51.2% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 30 September 2026, the fails-to-deliver balance in ORGO is 453 shares, down 67,596 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (17 July 2026) to 85,841 shares (14 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-30 | 453 | $1.39 | $630 |
| 2026-09-25 | 68,049 | $1.42 | $97K |
| 2026-09-22 | 15,274 | $1.40 | $21K |
| 2026-09-21 | 15,375 | $1.42 | $22K |
| 2026-09-14 | 85,841 | $1.49 | $128K |
| 2026-09-11 | 4,035 | $1.53 | $6K |
| 2026-09-10 | 40,690 | $1.57 | $64K |
| 2026-09-09 | 281 | $1.60 | $450 |
| 2026-09-01 | 1,564 | $1.72 | $3K |
| 2026-08-31 | 5,870 | $1.74 | $10K |
| 2026-08-26 | 1,690 | $1.74 | $3K |
| 2026-08-20 | 55,353 | $1.91 | $106K |
| 2026-08-17 | 29 | $1.79 | $52 |
| 2026-07-22 | 21 | $2.68 | $56 |
| 2026-07-17 | 1 | $2.67 | $3 |
| 2026-07-09 | 532 | $2.47 | $1K |
| 2026-07-08 | 532 | $2.50 | $1K |
| 2026-07-07 | 2,548 | $2.48 | $6K |
| 2026-07-01 | 3,745 | $2.43 | $9K |
| 2026-06-26 | 213 | $2.43 | $518 |
| 2026-06-25 | 213 | $2.44 | $520 |
| 2026-06-22 | 3,298 | $2.44 | $8K |
| 2026-06-15 | 1,052 | $2.34 | $2K |
| 2026-06-10 | 19,996 | $2.48 | $50K |
| 2026-06-09 | 997 | $2.38 | $2K |
| 2026-06-05 | 23 | $2.48 | $57 |
| 2026-06-02 | 8,060 | $2.36 | $19K |
| 2026-05-29 | 95 | $2.62 | $249 |
| 2026-05-27 | 630 | $2.66 | $2K |
| 2026-05-19 | 105 | $2.48 | $260 |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for ORGO in the last 90 days. The most recent filings are listed below. Latest filing: Leibowitz Arthur S (Director) on 2026-03-09.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-03-09 | Leibowitz Arthur S | Director | Buy | 5K | $2.68 | $13K | 291K |
| 2026-03-09 | Driscoll Michael Joseph | Director | Buy | 10K | $2.67 | $27K | 226K |
| 2026-03-01 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 700 | $3.21 | $2K | 276K |
| 2026-02-18 | Freedman Lori | Chief Admin. and Legal Officer | Tax withholding | 14K | $3.84 | $55K | 1.0M |
| 2026-02-18 | Freedman Lori | Chief Admin. and Legal Officer | Grant | 43K | $0.00 | $0 | 1.0M |
| 2026-02-18 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 5K | $3.84 | $21K | 276K |
| 2026-02-18 | Cavorsi Robert | Vice President, Strategy | Grant | 16K | $0.00 | $0 | 282K |
| 2026-02-18 | Francisco David | Chief Financial Officer | Grant | 44K | $0.00 | $0 | 746K |
| 2026-02-18 | Francisco David | Chief Financial Officer | Tax withholding | 15K | $3.84 | $56K | 731K |
| 2026-02-18 | Bilbo Patrick | Chief Operating Officer | Tax withholding | 16K | $3.84 | $63K | 1.1M |
| 2026-02-18 | Bilbo Patrick | Chief Operating Officer | Grant | 49K | $0.00 | $0 | 1.1M |
| 2026-02-18 | Grow Brian | Chief Commercial Officer | Grant | 49K | $0.00 | $0 | 912K |
| 2026-02-18 | Grow Brian | Chief Commercial Officer | Tax withholding | 12K | $3.84 | $46K | 900K |
| 2026-02-18 | Gillheeney Gary S. | President and CEO | Grant | 189K | $0.00 | $0 | 4.3M |
| 2026-02-18 | Gillheeney Gary S. | President and CEO | Tax withholding | 91K | $3.84 | $351K | 4.2M |
| 2026-02-18 | Montecalvo Antonio S. | Vice President, Health Policy | Grant | 11K | $0.00 | $0 | 230K |
| 2026-02-18 | Montecalvo Antonio S. | Vice President, Health Policy | Tax withholding | 4K | $3.84 | $15K | 226K |
| 2026-02-18 | Quintero Gilberto | Director | Grant | 49K | $0.00 | $0 | 239K |
| 2026-02-18 | Montecalvo Antonio S. | Vice President, Health Policy | Tax withholding | 4K | $3.84 | $14K | 226K |
| 2026-02-18 | Montecalvo Antonio S. | Vice President, Health Policy | Grant | 11K | $0.00 | $0 | 230K |
| 2026-02-18 | Montecalvo Antonio S. | Vice President, Health Policy | Grant | 41K | $0.00 | $0 | 219K |
| 2026-02-18 | Lustig Garrett | Director | Grant | 49K | $0.00 | $0 | 126K |
| 2026-02-18 | Leibowitz Arthur S | Director | Grant | 49K | $0.00 | $0 | 286K |
| 2026-02-18 | Korfin Michele Ilene | Director | Grant | 49K | $0.00 | $0 | 239K |
| 2026-02-18 | Grow Brian | Chief Commercial Officer | Tax withholding | 12K | $3.84 | $45K | 899K |
| 2026-02-18 | Grow Brian | Chief Commercial Officer | Grant | 48K | $0.00 | $0 | 911K |
| 2026-02-18 | Grow Brian | Chief Commercial Officer | Grant | 234K | $0.00 | $0 | 863K |
| 2026-02-18 | Gillheeney Gary S. | President and CEO | Tax withholding | 90K | $3.84 | $347K | 4.2M |
| 2026-02-18 | Gillheeney Gary S. | President and CEO | Grant | 187K | $0.00 | $0 | 4.3M |
| 2026-02-18 | Gillheeney Gary S. | President and CEO | Grant | 891K | $0.00 | $0 | 4.1M |
| 2026-02-18 | Giacomin Jon L | Director | Grant | 49K | $0.00 | $0 | 241K |
| 2026-02-18 | Freedman Lori | Chief Admin. and Legal Officer | Tax withholding | 14K | $3.84 | $55K | 1.0M |
| 2026-02-18 | Freedman Lori | Chief Admin. and Legal Officer | Grant | 43K | $0.00 | $0 | 1.0M |
| 2026-02-18 | Freedman Lori | Chief Admin. and Legal Officer | Grant | 203K | $0.00 | $0 | 995K |
| 2026-02-18 | Francisco David | Chief Financial Officer | Tax withholding | 15K | $3.84 | $56K | 731K |
| 2026-02-18 | Francisco David | Chief Financial Officer | Grant | 44K | $0.00 | $0 | 746K |
| 2026-02-18 | Francisco David | Chief Financial Officer | Grant | 195K | $0.00 | $0 | 702K |
| 2026-02-18 | Duraibabu Prathyusha | Director | Grant | 49K | $0.00 | $0 | 247K |
| 2026-02-18 | Driscoll Michael Joseph | Director | Grant | 49K | $0.00 | $0 | 216K |
| 2026-02-18 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 5K | $3.84 | $21K | 276K |
| 2026-02-18 | Cavorsi Robert | Vice President, Strategy | Grant | 16K | $0.00 | $0 | 282K |
| 2026-02-18 | Cavorsi Robert | Vice President, Strategy | Grant | 94K | $0.00 | $0 | 265K |
| 2026-02-18 | Bilbo Patrick | Chief Operating Officer | Tax withholding | 16K | $3.84 | $62K | 1.1M |
| 2026-02-18 | Bilbo Patrick | Chief Operating Officer | Grant | 49K | $0.00 | $0 | 1.1M |
| 2026-02-18 | Bilbo Patrick | Chief Operating Officer | Grant | 211K | $0.00 | $0 | 1.1M |
| 2026-02-15 | Montecalvo Antonio S. | Vice President, Health Policy | Tax withholding | 4K | $3.73 | $13K | 178K |
| 2026-02-15 | Montecalvo Antonio S. | Vice President, Health Policy | Tax withholding | 4K | $3.73 | $15K | 182K |
| 2026-02-15 | Montecalvo Antonio S. | Vice President, Health Policy | Tax withholding | 10K | $3.73 | $36K | 186K |
| 2026-02-15 | Montecalvo Antonio S. | Vice President, Health Policy | Tax withholding | 1K | $3.73 | $5K | 195K |
| 2026-02-15 | Grow Brian | Chief Commercial Officer | Tax withholding | 11K | $3.73 | $42K | 628K |
| 2026-02-15 | Grow Brian | Chief Commercial Officer | Tax withholding | 11K | $3.73 | $39K | 640K |
| 2026-02-15 | Grow Brian | Chief Commercial Officer | Tax withholding | 19K | $3.73 | $71K | 650K |
| 2026-02-15 | Grow Brian | Chief Commercial Officer | Tax withholding | 3K | $3.73 | $12K | 669K |
| 2026-02-15 | Gillheeney Gary S. | President and CEO | Tax withholding | 86K | $3.73 | $319K | 3.2M |
| 2026-02-15 | Gillheeney Gary S. | President and CEO | Tax withholding | 83K | $3.73 | $309K | 3.3M |
| 2026-02-15 | Gillheeney Gary S. | President and CEO | Tax withholding | 79K | $3.73 | $293K | 3.4M |
| 2026-02-15 | Gillheeney Gary S. | President and CEO | Tax withholding | 24K | $3.73 | $91K | 3.5M |
| 2026-02-15 | Freedman Lori | Chief Admin. and Legal Officer | Tax withholding | 14K | $3.73 | $50K | 792K |
| 2026-02-15 | Freedman Lori | Chief Admin. and Legal Officer | Tax withholding | 13K | $3.73 | $48K | 805K |
| 2026-02-15 | Freedman Lori | Chief Admin. and Legal Officer | Tax withholding | 24K | $3.73 | $91K | 818K |
| 2026-02-15 | Freedman Lori | Chief Admin. and Legal Officer | Tax withholding | 4K | $3.73 | $15K | 842K |
| 2026-02-15 | Francisco David | Chief Financial Officer | Tax withholding | 14K | $3.73 | $51K | 507K |
| 2026-02-15 | Francisco David | Chief Financial Officer | Tax withholding | 13K | $3.73 | $50K | 520K |
| 2026-02-15 | Francisco David | Chief Financial Officer | Tax withholding | 21K | $3.73 | $80K | 534K |
| 2026-02-15 | Francisco David | Chief Financial Officer | Tax withholding | 4K | $3.73 | $15K | 555K |
| 2026-02-15 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 5K | $3.73 | $20K | 172K |
| 2026-02-15 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 6K | $3.73 | $21K | 177K |
| 2026-02-15 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 7K | $3.73 | $25K | 182K |
| 2026-02-15 | Bilbo Patrick | Chief Operating Officer | Tax withholding | 15K | $3.73 | $57K | 885K |
| 2026-02-15 | Bilbo Patrick | Chief Operating Officer | Tax withholding | 16K | $3.73 | $58K | 900K |
| 2026-02-15 | Bilbo Patrick | Chief Operating Officer | Tax withholding | 28K | $3.73 | $106K | 916K |
| 2026-02-15 | Bilbo Patrick | Chief Operating Officer | Tax withholding | 5K | $3.73 | $19K | 944K |
| 2025-12-16 | NUSSDORF GLENN H | Director | Sell | 200K | $5.14 | $1.0M | 2.6M |
| 2025-11-26 | NUSSDORF GLENN H | Director, 10% owner | Sell | 188K | $5.29 | $994K | 2.8M |
| 2025-11-25 | NUSSDORF GLENN H | Director, 10% owner | Sell | 12K | $5.30 | $64K | 3.0M |
| 2025-11-24 | NUSSDORF GLENN H | Director, 10% owner | Sell | 100K | $5.34 | $534K | 3.0M |
| 2025-08-11 | Grow Brian | Chief Commercial Officer | Tax withholding | 2K | $4.62 | $10K | 672K |
| 2025-08-11 | Grow Brian | Chief Commercial Officer | Exercise or conversion | 4K | $2.47 | $10K | 675K |
| 2025-07-16 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 360 | $4.46 | $2K | 189K |
| 2025-06-10 | NUSSDORF GLENN H | Director, 10% owner | Sell | 19K | $3.56 | $66K | 336K |
| 2025-06-09 | NUSSDORF GLENN H | Director, 10% owner | Sell | 4K | $3.50 | $15K | 354K |
| 2025-06-06 | Freedman Lori | Chief Admin. and Legal Officer | Buy | 9K | $2.99 | $27K | 846K |
| 2025-06-05 | Freedman Lori | Chief Admin. and Legal Officer | Buy | 142K | $2.91 | $414K | 837K |
| 2025-06-04 | Freedman Lori | Chief Admin. and Legal Officer | Buy | 101K | $2.82 | $284K | 695K |
| 2025-05-15 | NUSSDORF GLENN H | Director, 10% owner | Buy | 107K | $2.99 | $321K | 358K |
| 2025-05-14 | NUSSDORF GLENN H | Director, 10% owner | Buy | 251K | $3.09 | $775K | 251K |
| 2025-03-09 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 61 | $5.16 | $315 | 190K |
| 2025-03-09 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 210 | $5.16 | $1K | 190K |
| 2025-03-04 | Driscoll Michael Joseph | Director | Sell | 25K | $5.10 | $128K | 167K |
| 2025-03-01 | Cavorsi Robert | Vice President, Strategy | Tax withholding | 667 | $6.21 | $4K | 190K |
| 2025-02-19 | Driscoll Michael Joseph | Director | Grant | 50K | $0.00 | $0 | 192K |
| 2025-02-19 | Duraibabu Prathyusha | Director | Grant | 50K | $0.00 | $0 | 198K |
| 2025-02-19 | Giacomin Jon L | Director | Grant | 50K | $0.00 | $0 | 192K |
| 2025-02-19 | Gillheeney Gary S. | President and CEO | Grant | 708K | $0.00 | $0 | 3.5M |
| 2025-02-19 | Korfin Michele Ilene | Director | Grant | 50K | $0.00 | $0 | 190K |
| 2025-02-19 | Leibowitz Arthur S | Director | Grant | 50K | $0.00 | $0 | 237K |
| 2025-02-19 | Lustig Garrett | Director | Grant | 50K | $0.00 | $0 | 77K |
| 2025-02-19 | Quintero Gilberto | Director | Grant | 50K | $0.00 | $0 | 190K |
| 2025-02-19 | Francisco David | Chief Financial Officer | Grant | 165K | $0.00 | $0 | 559K |
| 2025-02-19 | Freedman Lori | Chief Admin. and Legal Officer | Grant | 162K | $0.00 | $0 | 594K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON3 Form 144 notices on file for ORGO worth $2.6M at the prices reported; 0 in the last 90 days worth $0. Latest: Glenn Nussdorf filed on 2025-12-16 to sell 200,000 shares ($1.0M) from 2025-12-16.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2025-12-16 | Glenn NussdorfDirector, Stakeholder | 200K | $1.0M | 0.158% | 2025-12-16 | UBS Financial Services Inc |
| 2025-11-25 | Glenn NussdorfDirector, Stakeholder | 200K | $1.1M | 0.158% | 2025-11-25 | UBS Financial Services Inc |
| 2025-11-24 | Glenn NussdorfDirector, Stakeholder | 100K | $534K | 0.079% | 2025-11-24 | UBS Financial Services Inc |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON8 holders report 5% or more of ORGO in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Glenn H. Nussdorf at 9.7% of the class (12,248,560 shares), filed 2025-11-03 for an event on 2025-05-14.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-02-17 | 13G/Ano. 1 | Mathew P. Arensindividual | 3.9M | 3.1% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | First Light Asset Management, LLCinvestment adviser | 3.6M | 2.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital, LLCother entity | 10.0M | 7.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital Group, LLCother entity | 10.0M | 7.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus GP, LLCother entity | 10.0M | 7.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Guy Levyindividual | 10.0M | 7.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital Management, L.P.partnership | 10.0M | 7.9% | 2025-12-31 |
| 2026-02-12 | 13G/Ano. 5 | Soleus Capital Master Fund, L.P.non-US institution | 10.0M | 7.9% | 2025-12-31 |
| 2025-11-03 | 13D/Ano. 11 | Glenn H. Nussdorfindividual, other entity | 12.2M | 9.7% | 2025-05-14 |
| 2025-11-03 | 13D/Ano. 11 | GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016other entity | 7.9M | 6.2% | 2025-05-14 |
| 2025-11-03 | 13D/Ano. 11 | GN 2016 Family Trust u/a/d August 12, 2016other entity | 919K | 0.7% | 2025-05-14 |
13F holders
Tracked managers holding ORGO at their latest 13F. JSON5 of the 30 tracked managers held ORGO at their latest 13F, $18.9M in total at quarter-end prices. AQR Capital Management is the largest at $7.3M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| AQR Capital Management | 2026-06-30 | 3.0M | $7.3M | 0.00% | +2.1M |
| D. E. Shaw & Co. | 2026-06-30 | 2.9M | $7.0M | 0.00% | +590K |
| Renaissance Technologies | 2026-06-30 | 1.0M | $2.5M | 0.00% | -51K |
| Citadel Advisors | 2026-06-30 | 868K | $2.1M | 0.00% | +324K |
| Two Sigma Investments | 2026-06-30 | 11K | $28K | 0.00% | -16K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Organogenesis Holdings reported revenue of $43.8M, down 56.7% from the same quarter a year earlier, and net loss of $96.3M (-0.77 diluted EPS). In FY 2025 it generated -$10.3M of operating cash flow.
- Cash
- $46.1M
- Equity
- $148.3M
- Total assets
- $406.4M
- Shares outstanding
- 128,674,548
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $43.8M | -$96.3M | -220.0% | -0.77 |
| Q1 FY 2026 | 2026-03-31 | $37.2M | -$53.2M | -142.8% | -0.44 |
| Q4 FY 2025derived | 2025-12-31 | $225.6M | $43.7M | 19.4% | n/a |
| Q3 FY 2025 | 2025-09-30 | $150.9M | $21.6M | 14.3% | 0.11 |
| Q2 FY 2025 | 2025-06-30 | $101.0M | -$9.4M | -9.3% | -0.10 |
| Q1 FY 2025 | 2025-03-31 | $86.7M | -$18.8M | -21.7% | -0.17 |
| Q4 FY 2024derived | 2024-12-31 | $126.7M | $7.7M | 6.1% | n/a |
| Q3 FY 2024 | 2024-09-30 | $115.2M | $12.3M | 10.7% | 0.09 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $564.2M | $37.0M | -$10.3M | $14.2M | n/a | n/a |
| FY 2024 | 2024-12-31 | $482.0M | $861K | $14.2M | $10.0M | $25.5M | n/a |
| FY 2023 | 2023-12-31 | $433.1M | $4.9M | $30.9M | $24.4M | $0 | n/a |
| FY 2022 | 2022-12-31 | $450.9M | $15.5M | $24.9M | $33.9M | $0 | n/a |
| FY 2021 | 2021-12-31 | $467.4M | $94.2M | $62.0M | $31.2M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-31 from the cover page.
What this page is
Organogenesis Holdings in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Organogenesis Holdings (ORGO), SEC CIK 1661181, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-30.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2025-12-16.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-02-17.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-06.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-03-09.JSON and CSV
- Company record
- EDGAR filing index for CIK 1661181Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ORGO is sold short?
15,590,713 shares were held short at the 2026-10-15 settlement, 21.2 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ORGO's daily short volume?
On 2026-11-02, 323,719 of the 668,834 ORGO shares reported to FINRA were sold short, 48.4% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ORGO have fails to deliver?
The SEC's latest file shows 453 ORGO shares failed to deliver at settlement 2026-09-30. Fails are reported per settlement date and published twice a month with a lag.
Are ORGO insiders buying or selling?
No open-market insider trades were reported for ORGO in the last 90 days. The most recent filings are listed below. Latest filing: Leibowitz Arthur S (Director) on 2026-03-09.
Have ORGO insiders filed to sell?
3 Form 144 notices on file for ORGO worth $2.6M at the prices reported; 0 in the last 90 days worth $0. Latest: Glenn Nussdorf filed on 2025-12-16 to sell 200,000 shares ($1.0M) from 2025-12-16.
Who owns 5% or more of ORGO?
8 holders report 5% or more of ORGO in their latest filing, 2 on Schedule 13D (active intent). The largest reported stake is Glenn H. Nussdorf at 9.7% of the class (12,248,560 shares), filed 2025-11-03 for an event on 2025-05-14.
What did ORGO report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Organogenesis Holdings reported revenue of $43.8M, down 56.7% from the same quarter a year earlier, and net loss of $96.3M (-0.77 diluted EPS). In FY 2025 it generated -$10.3M of operating cash flow.
Which tracked 13F managers own ORGO?
5 of the 30 tracked 13F managers held ORGO shares at their latest filing, $18.9M in all. The largest: Cliff Asness's AQR Capital Management (3.0M shares, $7.3M), D. E. Shaw & Co. (2.9M shares, $7.0M), Renaissance Technologies (1.0M shares, $2.5M), Ken Griffin's Citadel Advisors (868K shares, $2.1M), Two Sigma Investments (11K shares, $28K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.